These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9715276)

  • 1. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
    Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
    Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site.
    Santoro MM; Penengo L; Orecchia S; Cilli M; Gaudino G
    Oncogene; 2000 Oct; 19(45):5208-11. PubMed ID: 11064459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.
    Chiariello M; Visconti R; Carlomagno F; Melillo RM; Bucci C; de Franciscis V; Fox GM; Jing S; Coso OA; Gutkind JS; Fusco A; Santoro M
    Oncogene; 1998 May; 16(19):2435-45. PubMed ID: 9627110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
    Peace BE; Hughes MJ; Degen SJ; Waltz SE
    Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
    Iwama A; Yamaguchi N; Suda T
    EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
    Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
    J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.
    Danilkovitch-Miagkova A; Miagkov A; Skeel A; Nakaigawa N; Zbar B; Leonard EJ
    Mol Cell Biol; 2001 Sep; 21(17):5857-68. PubMed ID: 11486025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
    Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
    Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
    Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
    J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
    Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
    Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
    Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
    Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.
    Plattner R; Gupta S; Khosravi-Far R; Sato KY; Perucho M; Der CJ; Stanbridge EJ
    Oncogene; 1999 Mar; 18(10):1807-17. PubMed ID: 10086335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between the proto-oncogenes Met and Ron.
    Follenzi A; Bakovic S; Gual P; Stella MC; Longati P; Comoglio PM
    Oncogene; 2000 Jun; 19(27):3041-9. PubMed ID: 10871856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic signaling pathways activated by RON receptor tyrosine kinase.
    Danilkovitch-Miagkova A
    Curr Cancer Drug Targets; 2003 Feb; 3(1):31-40. PubMed ID: 12570659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Dok1 in cell signaling mediated by RET tyrosine kinase.
    Murakami H; Yamamura Y; Shimono Y; Kawai K; Kurokawa K; Takahashi M
    J Biol Chem; 2002 Sep; 277(36):32781-90. PubMed ID: 12087092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.